⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRD News
Opus Genetics, Inc. Common Stock
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
globenewswire.com
IRD
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
globenewswire.com
IRD
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
globenewswire.com
IRD
Opus Genetics to Participate in Leading Medical Conferences in May 2026
globenewswire.com
IRD
Form 8-K
sec.gov
IRD
Form 8-K
sec.gov
IRD
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
globenewswire.com
IRD
VTRS
Form 8-K
sec.gov
IRD
Form 8-K
sec.gov
IRD
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
globenewswire.com
IRD